Artificial intelligence is still struggling to crack the most complex problem in pharma R&D: reliably designing new molecules that become breakthrough medicines. But drugmakers say AI is already paying off in the “unsexy” middle of development. This is where time and money are often lost to paperwork, vendor hand-offs, and slow trial start-up. At the JPMorgan Healthcare Conference in January…
Tag: AstraZeneca
-
Immunotherapy for Cancer and Early-Stage Success
Ground-breaking advancements in immunotherapy are poised to transform cancer care. New data reveal the effectiveness of these immune-boosting drugs in treating a wider range of cancers at their earlier stages. Previously established as life-extending treatments for advanced diseases, drugs such as Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, and Roche’s Tecentriq are now demonstrating significant promise. They are preventing recurrence and…